Holen Sie sich die Stockscreener-App
18.94
1.83%
0.34
Schlusskurs vom Vortag:
$18.60
Offen:
$19.82
24-Stunden-Volumen:
6.50M
Relative Volume:
1.79
Marktkapitalisierung:
$14.07B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-59.19
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
-27.10%
1M Leistung:
-26.26%
6M Leistung:
-4.87%
1J Leistung:
-30.90%
1-Tages-Spanne:
$18.58
$19.97
1-Wochen-Bereich:
$16.31
$22.78
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.94 | 13.08B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Siren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2%Should You Sell? - MarketBeat
Adage Capital Partners GP L.L.C. Invests $10.38 Million in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) Shares Surge After CEO Stock Purchases - GuruFocus
Summit Therapeutics Stock (SMMT) Opinions on HARMONi Trial Data Release - Quiver Quantitative
Summit Therapeutics stock gains on insider buys (SMMT:NASDAQ) - Seeking Alpha
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m By Investing.com - Investing.com Nigeria
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m - Investing.com
Summit Therapeutics director Zanganeh buys shares worth $5.9m - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating - MSN
Polar Asset Management Partners Inc. Decreases Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Vident Advisory LLC Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - FinancialContent
Summit’s Stock Plunge: What Lies Ahead? - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Summit Therapeutics' (SMMT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions - Yahoo Finance
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
What’s the fair value of Summit Therapeutics Inc. stock2025 Sector Review & High Accuracy Swing Entry Alerts - Lancaster City Council
Summit Therapeutics Inc. Investors: Please contact the - GlobeNewswire
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study - The Globe and Mail
Top 3 Health Care Stocks You'll Regret Missing In Q3 - Benzinga
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
First disclosure of Phase II data for pumitamig - The Pharma Letter
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
Akeso's Lung Cancer Drug Faces US Approval Hurdles - Finimize
Cutter Capital Management LP Acquires New Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingJuly 2025 Highlights & Advanced Technical Analysis Signals - beatles.ru
Summit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT) - MarketBeat
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Summit's High-Profile Drug Flops And Shares Crash - Investor's Business Daily
Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health - TheStreet
Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts - Endpoints News
Top Midday Decliners - MarketScreener
Summit Therapeutics Enters Oversold Territory (SMMT) - Nasdaq
Summit Therapeutics Breaks Below 200-Day Moving AverageNotable for SMMT - Nasdaq
Transcript : Summit Therapeutics Inc.Special Call - MarketScreener
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions - BioSpace
Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward - Seeking Alpha
Summit Therapeutics Shares Plunge After Lung Cancer Drug Data Disappoints - MSN
Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner - Bloomberg.com
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch - MSN
Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics - Yahoo Finance
Summit Therapeutics stock rises as H.C. Wainwright reiterates Buy rating - Investing.com
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $30 to $50 - 富途牛牛
Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize
Summit Therapeutics Reveals Promising Phase III Trial Results - TipRanks
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Yahoo Finance
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):